Risk of infections in renal cell carcinoma (RCC) and non-RCC patients treated with mammalian target of rapamycin inhibitors

BACKGROUND: Mammalian target of rapamycin (mTOR) inhibitors are used in a variety of malignancies. Infections have been reported with these drugs. We performed an up-to-date meta-analysis to further characterise the risk of infections in cancer patients treated with these agents. METHODS: Pubmed and...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaymakcalan, M D, Je, Y, Sonpavde, G, Galsky, M, Nguyen, P L, Heng, D Y C, Richards, C J, Choueiri, T K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3694254/
https://www.ncbi.nlm.nih.gov/pubmed/23736025
http://dx.doi.org/10.1038/bjc.2013.278

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3694254/
https://www.ncbi.nlm.nih.gov/pubmed/23736025
http://dx.doi.org/10.1038/bjc.2013.278

Ejemplares similares